Filing Details

Accession Number:
0001140361-15-018423
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-05-08 13:07:46
Reporting Period:
2015-05-06
Filing Date:
2015-05-08
Accepted Time:
2015-05-08 13:07:46
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1425205 Lion Biotechnologies Inc. LBIO Biological Products, (No Disgnostic Substances) (2836) 753254381
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1471149 Ayer Capital Management, Lp 616 Corporate Way, Suite 2-4931
Valley Cottage NY 10989
No No Yes No
1519940 Acm Capital Partners, Llc 616 Corporate Way, Suite 2-4931
Valley Cottage NY 10989
No No Yes No
1519942 Ayer Capital Partners, Llc 616 Corporate Way, Suite 2-4931
Valley Cottage NY 10989
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2015-05-01 2,780,682 $9.62 2,823,333 No 4 S Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See Footnote
Footnotes
  1. These securities are held by investment funds and a managed account, the investment advisor of which is Ayer Capital Management, LP (the "Advisor"), ACM Capital Partners, LLC ("ACM")is the General Partner of the Advisor, Ayer Capital Partners, LLC (the "GP") is the General Partner of the investment funds. Mr. Venkatesan is the managing member of ACM and the General Partner of the GP.
  2. Each of the Advisor, ACM, the GP, and Mr. Venkatesan disclaims beneficial ownership of these securities except to the extent of its or his pecuniary interest thereof, and the filing of this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purpose.
  3. The sale of securities were sold in an underwritten secondary offering of 4,750,000 shares of Lion's common stock at a price to the public of $10.00 per share with a 0.375 gross spread to the underwriters. All shares were offered by the selling stockholders, including certain members of Board of Directors of the Company and certain of their affiliates. Lion Biotechnologies will not sell any shares or receive any proceeds from the offering.